EGFR TKI耐药后人群,有什么新的治疗选择?
CN-Healthcare,
不同EGFR TKI耐药机制的患者中,HER3-DXd均显示出较高的ORR。 2023 WCLC 带来的思考 2023年9月9日-9月12日,多项重磅研究在WCLC大会公布了最新结果。其中,抗HER3 ADC药物Patritumab Deruxtecan(H…
不同EGFR TKI耐药机制的患者中,HER3-DXd均显示出较高的ORR。 2023 WCLC 带来的思考 2023年9月9日-9月12日,多项重磅研究在WCLC大会公布了最新结果。其中,抗HER3 ADC药物Patritumab Deruxtecan(H…
1. The objective response rate was 29.8% (1% complete response, 66% partial response) with a PFS of 5.5 months and a median OS…
Meeting Coverage > IASLC Confirmed responses reached 29.8% in heavily pretreated patients by Mike Bassett, Staff Writer…
SINGAPORE – Heavily pretreated patients with EGFR-mutated non–small cell lung cancer (NSCLC) may experience a clinically…
SINGAPORE — Heavily pretreated patients with EGFR-mutated non–small cell lung cancer (NSCLC) may experience a clinically…
By Clinical Content Hub Erika Hamilton, MDSarah Cannon Research Institute, Nashville, Tennessee Key Takeaways Patients with…
Summary Daiichi Sankyo is leading the world in the development of antibody-drug conjugates, which are finally paying off in…
ADC药物被称为抗肿瘤"魔法子弹" ADC药物的主要构成:抗体,链接子和细胞毒素三部分组成: 1 抗体组成部分 抗体可以特异性的靶向特定抗原,该抗原在肿瘤细胞内表达,而在正常细胞内不表达或低表达。而且应具有和其他组织细胞最低的非特异结合活性。抗体在整个ADC…
HER3 has been shown to have a small amount of tyrosine kinase activity, making it an attractive target for the treatment of…
Results from the phase 1/2 U31402-J101 trial (NCT02980341) showed positive responses in patients with metastatic HER3-expressing…
Patritumab deruxtecan produced encouraging responses in patients with HER3-expressing metastatic breast cancer or metastatic…
Disease progression and acquired resistance to approved EGFR tyrosine kinase inhibitors have resulted in a treatment void in…
The FDA has granted a breakthrough therapy designation to patritumab deruxtecan for the treatment of patients with metastatic…